Clinical trial · Interventional
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
NCT05433090CI-TRIAL-00106905Inpatient SICPcompletedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot study to assess the preliminary efficacy of an inpatient advance care planning intervention on outcomes in older patients with hematologic malignancies
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Inpatient serious illness care program | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental
- description
- Patients will participate in an inpatient advance care planning intervention.
- interventionNames
- Behavioral: Inpatient serious illness care program
Primary outcomes (1)
- measure
- Retention Rate
- timeFrame
- From consent until completion of the ACP intervention visit, usually within 1 week.
- description
- Retention rate is the percentage of consented patients who completed the ACP intervention visit. A retention rate of \>70% was considered feasible.
Secondary outcomes (2)
- measure
- Advance Directive Completion - HCP
- timeFrame
- From baseline (pre-intervention) to 1 year post-intervention. The time interval is approximately 1 year.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥60 years * A diagnosis of hematologic malignancy \[including but not limited to acute leukemia, myeloid malignancies (e.g., atypical CML, MDS/MPN overlap syndromes, CMML), multiple myeloma, lymphoma, or any other hematologic malignancies based on the primary oncologist's judgment\] * Able to provide informed consent * Being managed in the inpatient setting * English-speaking Exclusion Criteria: • None
References
Publications (3)
- BACKGROUNDLoCastro M, Baran AM, Liesveld JL, Huselton E, Becker MW, O'Dwyer KM, Aljitawi OS, Baumgart M, Snyder E, Kluger B, Loh KP, Mendler JH. Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes. Blood Adv. 2021 Dec 28;5(24):5554-5564. doi: 10.1182/bloodadvances.2021004775. PMID 34525170
- RESULTMarissa Locastro, Ying Wang, Soroush Mortaz-Hedjri, Danielle Frumusa, Tracy Natale, Jessica Cohen, Nicole Yates, Jenna Podlucky, Tristan Yu, Thomas Carroll, Jane L. Liesveld, Megan Baumgart, Sandra Sabtka, Dwight Hettler, Nicole Kaplan, Jason H. Mendler, Kah Poh Loh; An Inpatient Advance Care Planning Intervention for Older Patients with Hematologic Malignancies: A Single-Arm Pilot Study. Blood 2024; 144 (Supplement 1): 5054. doi: https://doi.org/10.1182/blood-2024-206137
- DERIVEDLoCastro M, Wang Y, Baran A, Mortaz Hedjri S, Frumusa D, Natale T, Cohen J, Yates N, Podlucky J, Yu T, Carroll T, Liesveld J, Baumgart M, Sabatka S, Hettler D, Kaplan N, Mendler JH, Loh KP. An inpatient Serious Illness Care Program for older patients with hematologic malignancies: a single-arm pilot study. Blood Adv. 2026 Jun 23;10(12):4412-4422. doi: 10.1182/bloodadvances.2025018200. PMID 41949389